Laboratory Products
Exploring the Value of Biomarkers in Drug Discovery
Mar 19 2010
The latest addition to Quotient Bioresearch’s ongoing ‘Evidence’ information series is now available for download. Biomarkers in Respiratory Disease – Part 1: Chronic Obstructive Pulmonary Disease (COPD) is the first white paper in a new series that will explore the value that biomarkers can add to drug discovery and development in important therapeutic areas.
The programme includes print and e-newsletters that regularly review the company’s scientific publications, as well as presentations on Quotient Bioresearch expertise and unique integrated clinical service offering – Synthesis-to-Clinic™.
COPD is a global health issue that continues to be an important cause of morbidity, mortality, and health-care costs worldwide. In the UK, for example, it affects as many as three million people and is soon to be the subject of a new National Clinical Strategy approach from government and healthcare providers.
Understanding disease progression – and developing successful therapeutic interventions – requires extensive use of biomarkers. The new Quotient Bioresearch white paper discusses how the combination of biomarkers from three sub-pathologies (oxidative stress, inflammation and tissue remodelling) with physiological assessment of lung function may provide an early indication of disease modification, the long-time goal of many current and prospective COPD treatments.
Digital Edition
Lab Asia 31.4 August 2024
August 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers Labo...
View all digital editions
Events
Sep 04 2024 Chiba, Tokyo, Japan
Sep 04 2024 University of Warwick, Coventry, UK
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Singapore
Sep 11 2024 Bangkok, Thailand